Literature DB >> 15852371

Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Jan O Aasly1, Mathias Toft, Ignacio Fernandez-Mata, Jennifer Kachergus, Mary Hulihan, Linda R White, Matthew Farrer.   

Abstract

Several pathogenic mutations in the leucine-rich repeat kinase 2 (LRRK2; PARK8) gene recently have been identified in familial and sporadic parkinsonism. We screened 435 Norwegian patients diagnosed with Parkinson's disease and 519 control subjects for the presence of 7 LRRK2 mutations. Nine patients from seven families were found to be heterozygote carriers of the LRRK2 6055G>A (G2019S) mutation. Twelve of 28 first-degree relatives also carried the mutation, but only 1 had Parkinson's disease. The clinical features included asymmetric resting tremor, bradykinesia, and rigidity with a good response to levodopa and could not be distinguished from idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852371     DOI: 10.1002/ana.20456

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

2.  Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.

Authors:  Steven A Gunzler; David E Riley; Shu G Chen; Curtis M Tatsuoka; William M Johnson; John J Mieyal; Ellen M Walter; Christina M Whitney; I Jung Feng; Harry Owusu-Dapaah; Shivam O Mittal; Amy L Wilson-Delfosse
Journal:  J Neurol Sci       Date:  2018-03-17       Impact factor: 3.181

Review 3.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

4.  PINK1 mutation heterozygosity and the risk of Parkinson's disease.

Authors:  M Toft; R Myhre; L Pielsticker; L R White; J O Aasly; M J Farrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

Review 5.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 6.  Progress in the pathogenesis and genetics of Parkinson's disease.

Authors:  Yoshikuni Mizuno; Nobutaka Hattori; Shin-Ichiro Kubo; Shigeto Sato; Kenya Nishioka; Taku Hatano; Hiroyuki Tomiyama; Manabu Funayama; Yutaka Machida; Hideki Mochizuki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-27       Impact factor: 6.237

Review 7.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

8.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

Review 9.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

10.  Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.

Authors:  Xiaojie Li; Darren J Moore; Yulan Xiong; Ted M Dawson; Valina L Dawson
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.